NCT02434458

Brief Summary

The purpose of this study is to assess the diagnostic utility of Sudoscan in assessing small fiber nerve function, specifically those of the sudomotor, in patients with autoimmune disorders (i.e fibromyalgia and rheumatoid arthritis).

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
85

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started May 2015

Shorter than P25 for all trials

Geographic Reach
1 country

2 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

April 27, 2015

Completed
4 days until next milestone

Study Start

First participant enrolled

May 1, 2015

Completed
4 days until next milestone

First Posted

Study publicly available on registry

May 5, 2015

Completed
4 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 1, 2015

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

September 1, 2015

Completed
Last Updated

September 15, 2015

Status Verified

September 1, 2015

Enrollment Period

4 months

First QC Date

April 27, 2015

Last Update Submit

September 12, 2015

Conditions

Keywords

fibromyalgia,polyneuropathysmall fiber neuropathyrheumatoid arthritissudomotor

Outcome Measures

Primary Outcomes (1)

  • Sudoscan values

    Small fiber function from sweat glands, using Sudoscan

    once at time of enrollment

Secondary Outcomes (1)

  • NCS studies

    once at time of enrollment

Study Arms (3)

Fibromyalgia case group

Patients diagnosed with fibromyalgia from the department of rheumatology will be subject to sudoscan evaluation and NCS studies.

Control

Healthy control subjects

Rheumatoid arthritis group

Patients diagnosed with rheumatoid arthritis at the department of rheumatology will be subject to sudoscan evaluation and NCS studies.

Eligibility Criteria

Age18 Years - 80 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

patients who meet the following diagnostic criteria for either 1. Fibromyalgia or 2. Rheumatoid arthritis

You may qualify if:

  • A. for healthy control group
  • \- No previous diagnosis of peripheral polyneuropathy, fibromyalgia or rheumatoid arthritis
  • B. For case group
  • Fibromyalgia diagnosed by the rheumatology department
  • Rheumatoid arthritis diagnosed by the the rheumatology department.

You may not qualify if:

  • For control group
  • Participants with previously diagnosed with medical conditions that are known to cause peripheral polyneuropathy (i.e. diabetes mellitus, chronic renal failure, hepatitis, malnutrition), or participants taking medications related to peripheral polyneuropathy(chemoagents, anti Tbc medication) or manifest with symptoms and signs of tingling sensation and gait disturbance that indicate presence of underlying peripheral polyneuropathy.
  • For both control and case groups
  • Severe skin deficits or swelling that may impede nerve conduction study
  • Concomitant presence of mononeuropathy of the extremities.
  • Past surgical or traumatic episodes of the foot and distal extremities subject to nerve conduction study
  • History of chronic alcoholism, of history of heavy alcohol ingestion with the last 24 hours prior o exam
  • Pregnant status at time of evaluation
  • presence of pacemaker of defibrillator
  • physical inability to lay the palms of the hand and soles of the feet on the plate electrodes.
  • scars on the palm and soles of the feet that may impair recording from the plate electrodes
  • venous insufficiency, foot swelling or foot ulceration or infection
  • Abnormal fasting glucose or Vit B12, thyroid dysfunction, Vit D and abnormal levels of lipid profile, HbA1c \> 7
  • Medications with anticholinergics, TCA, anti-histamine, anti-muscarinic medication within the last 48hours
  • Patients currently taking Anti Parkinson agents, ranitidine, or other muscle relaxants, beta blockers and atropine
  • +1 more criteria

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

Bucheon St Mary's Hospital, Catholic University of Korea

Bucheon-si, Gyenoggido, 420-717, South Korea

Location

Bucheon St Mary's Hospital

Bucheon-si, South Korea

Location

MeSH Terms

Conditions

Autoimmune DiseasesFibromyalgiaPolyneuropathiesSmall Fiber NeuropathyArthritis, Rheumatoid

Condition Hierarchy (Ancestors)

Immune System DiseasesMuscular DiseasesMusculoskeletal DiseasesRheumatic DiseasesNeuromuscular DiseasesNervous System DiseasesPeripheral Nervous System DiseasesArthritisJoint DiseasesConnective Tissue DiseasesSkin and Connective Tissue Diseases

Study Officials

  • Su-Jin Monn, M.D., PhD

    Catholic University of Korea, College of Medicine Bucheon St. Mary's Hospital

    STUDY DIRECTOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
CROSS SECTIONAL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Assistant Professor

Study Record Dates

First Submitted

April 27, 2015

First Posted

May 5, 2015

Study Start

May 1, 2015

Primary Completion

September 1, 2015

Study Completion

September 1, 2015

Last Updated

September 15, 2015

Record last verified: 2015-09

Locations